Diseases [C] » Chemically-Induced Disorders [C25] » Substance-Related Disorders » Alcohol-Related Disorders » Alcoholism
Psychiatry and Psychology [F] » Mental Disorders [F03] » Substance-Related Disorders » Alcohol-Related Disorders » Alcoholism
Description
A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4) MeSH
Hierarchy View
Approved Indicated Drugs (6)
Phase 4 Indicated Drugs (46)
Phase 2 Indicated Drugs (69)
Other Experimental Indicated Drugs (23)
Organization Involved with Phase 4 Indications (92)
Asociación Civil Impacta Salud y Educación, Peru
Brain & Behavior Research Foundation
Catholic University of Sacred Heart, Rome
Finnish Foundation for Alcohol Studies
German Addiction Research Network
German Federal Ministry of Education and Research
Hoosier Cancer Research Network
Laboratorio Farmaceutico Ct S.r.l.
Mbarara University of Science and Technology
Medical University of South Carolina
National Center for Research Resources (NCRR)
New York Presbyterian Hospital
Northern California Institute of Research and Education
Sha'ar Menashe Mental Health Center
South Eastern Area Health Service
Stanley Medical Research Institute
State University of New York, Syracuse
St. Petersburg Bekhterev Research Psychoneurological Institute
Sydney South West Area Health Service
The University of Texas, Dallas
University of California, Los Angeles
Organization Involved with Phase 3 Indications (32)
Associacao Fundo de Incentivo a Psicofarmcologia
Lade Addiction Treatment Center
National Cheng Kung University
National Institute for Health and Welfare Research Center Biomedicum
National Institute on Drug Abuse (NIDA)
Norwegian University of Science and Technology
Oregon Health and Science University
Princess Mother National Institute on Drug Abuse and Treatment
Organization Involved with Phase 2 Indications (58)
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
Minnesota Veterans Medical Research and Education Foundation
National Center for Complementary and Integrative Health (NCCIH)
Pacific Neuroscience Institute
Pharmacotherapies for Alcohol and Substance Abuse Consortium
The Florey Institute of Neuroscience and Mental Health
The Novavi outpatient clinics, Copenhagen
Universidad Autonoma de Barcelona
Organization Involved with Phase 1 Indications (15)
Organization Involved with Other Experimental Indications (14)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
